Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL416280 | 1.00 | BLM (0.62) | BLMLMNAACE2PTPN1MEN1 | |
| SCHEMBL935526 | 0.82 | BLM (0.50) | BLMLMNAACE2PTPN1MEN1 | |
| Squalane SCHEMBL28338533 | 0.81 | BLM (0.69) | BLMLMNAACE2PTPN1MEN1 | |
| SCHEMBL27458546 | 0.78 | BLM (0.60) | BLMLMNAACE2PTPN1MEN1 | |
| SCHEMBL28238013 | 0.78 | BLM (0.60) | BLMLMNAACE2PTPN1MEN1 | |
| SCHEMBL28455451 | 0.78 | BLM (0.60) | BLMLMNAACE2PTPN1MEN1 | |
| Acetic Acid SCHEMBL20972332 | 0.78 | BLM (0.71) | BLMLMNAACE2PTPN1MEN1 | |
| SCHEMBL28455377 | 0.77 | BLM (0.58) | BLMLMNAACE2PTPN1MEN1 | |
| SCHEMBL14661585 | 0.77 | CA2 (0.50) | ACE2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL11600716 | 0.77 | BLM (1.00) | BLMLMNAACE2PTPN1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119517408-A | Method for establishing death prediction model of new-onset type 2 diabetes and application | 中南大学湘雅二医院 | 2025-02-25 | — | — | CN | claimed |
| US-20240260865-A1 | METHOD OF PRODUCING THIN ENZYME-BASED SENSING LAYERS ON PLANAR SENSORS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2024-08-08 | — | — | US | claimed |
| US-11969246-B2 | Method of producing thin enzyme-based sensing layers on planar sensors | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2024-04-30 | — | — | US | claimed |
| US-11903708-B2 | Switchable low voltage electrochemical sensing for interfering species rejection | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2024-02-20 | — | — | US | claimed |
| US-20230363672-A1 | METHOD OF PRODUCING THIN ENZYME-BASED SENSING LAYERS ON PLANAR SENSORS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2023-11-16 | — | — | US | claimed |
| US-11690544-B2 | Method of producing thin enzyme-based sensing layers on planar sensors | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-07-04 | — | — | US | claimed |
| US-20040138181-A1 | Phytanic acid derivative compositions and method of treating and/or preventing diabetes mellitus | ROCHE VITAMINS INC. | 2004-07-15 | — | — | US | claimed |
| CN-1365667-A | Use of phytanic acid for treating diabetes | ROCHE VITAMINE AG (CH) | 2002-08-28 | — | — | CN | claimed |
| US-20020082298-A1 | Phytanic acid derivative compositions and method of treating and/or preventing diabetes mellitus | F. HOFFMANN-LA ROCHE AG | 2002-06-27 | — | — | US | claimed |
| EP-1177789-A2 | Use of phytanic acid for the treatment of diabetes | Roche Vitamins AG (CH) | 2002-02-06 | — | — | EP | claimed |
| US-20260137646-A1 | PENTADECANOYLCARNITINE FOR TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | EPITRACKER INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4618746-A1 | ENZYMATICALLY PRODUCED BIOPESTICIDES | ZYMtronix Catalytic Systems, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12370166-B2 | Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity | Epitracker, Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250196115-A1 | MAGNETIC MACROPOROUS POLYMERIC HYBRID SCAFFOLDS FOR IMMOBILIZING BIONANOCATALYSTS | ZYMTRONIX CATALYTIC SYSTEMS, INC. (US) | 2025-06-19 | — | — | US | disclosed |
| US-20250120393-A1 | MAGNETICALLY IMMOBILIZED BIOCIDAL ENZYMES AND BIOCIDAL CHEMICALS | ZYMTRONIX CATALYTIC SYSTEMS, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-20040138181-A1 | Phytanic acid derivative compositions and method of treating and/or preventing diabetes mellitus | ROCHE VITAMINS INC. | 2004-07-15 | — | — | US | disclosed |
| CN-1365667-A | Use of phytanic acid for treating diabetes | ROCHE VITAMINE AG (CH) | 2002-08-28 | — | — | CN | disclosed |
| US-20020082298-A1 | Phytanic acid derivative compositions and method of treating and/or preventing diabetes mellitus | F. HOFFMANN-LA ROCHE AG | 2002-06-27 | — | — | US | disclosed |
| EP-1177789-A2 | Use of phytanic acid for the treatment of diabetes | Roche Vitamins AG (CH) | 2002-02-06 | — | — | EP | disclosed |
| WO-1997009039-A2 | COMPOSITION COMPRISING VITAMIN F | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137646-A1 | PENTADECANOYLCARNITINE FOR TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | HTR6, HTR2A, OPRL1 | BLM 2578/4885LMNA 3177/4885ACE2 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.